Discreet packaging
Plain outer packaging on every order.
Sold out, pre-orderResearch use onlyLongevity research
SLU-PP-332 Australia: 5mg Research Compound
SLU-PP-332 Australia stock at Glow Labs is a 5mg vial of a small synthetic molecule, not a peptide. It comes from Saint Louis University and switches on ERR nuclear receptors. Order or pre-order the 5mg vial with a WhatsApp message to our team. Vials go out tracked from Gippsland, Victoria, and delivery takes 2-3 days.
Size
Price confirmed on WhatsApp before you pay
Sold out Stocking soon. Message us to pre-order.
Research use only. Not for human consumption.
- No account needed
- Tracked, 2-3 days
- COA on request
Fast delivery, 2-3 days
Orders leave Traralgon in the afternoon during business hours, then travel tracked to your door.
Certificates on request
Certificates of analysis available on request.
Quality guarantee
If a vial arrives damaged, broken or not what you ordered, message us within 7 days with a photo and we'll replace it free.
What it is
Research overview
What SLU-PP-332 is
SLU-PP-332 is a benzohydrazide linked to a naphthalene ring. PubChem lists it as 4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide, with a mass of about 290 g/mol.
There are no amino acids in it. It is a classic drug-like small molecule.
Sources: PubChem compound record: SLU-PP-332 (CID 5338394), US National Library of Medicine.
Questions about SLU-PP-332?
Ask on WhatsAppWhat the studies examined
A 2023 paper in ACS Chemical Biology reported SLU-PP-332 as an agonist of all three estrogen-related receptors. These are ERR alpha, beta and gamma. It was most potent at ERR alpha. The team studied muscle cells and mice, looking at muscle fibre types and exercise endurance.
A 2024 follow-up in the Journal of Pharmacology and Experimental Therapeutics tested it in obese mouse models and measured energy use and fat oxidation.
In 2026 an anti-doping chemistry paper mapped its breakdown products using human liver enzymes in the lab. The authors did this because of its potential misuse in sport. No human trials appear in these papers.
Sources: Billon C et al, ACS Chem Biol, 2023. Billon C et al, A synthetic ERR agonist alleviates metabolic syndrome, J Pharmacol Exp Ther, 2024. Moller T et al, Rapid Commun Mass Spectrom, 2026.
Why sports testing labs study it
Because SLU-PP-332 was described as an exercise mimetic, anti-doping chemists in 2026 characterised it by high resolution mass spectrometry. They reported nine metabolites from human liver enzyme tests.
That work gives labs reference data for detecting the compound, which is useful for anyone confirming identity too.
Storing a small molecule
A peptide supplier's storage guide names moisture, heat and light as the main risks to stored solids. It was written for peptides, not small molecules, so read it as general advice: keep the sealed vial cool, dark and dry with desiccant.
Sources: JPT Peptide Technologies, How to store peptides: best practices for researchers.
Read the research guide
Specification
Product specs
| Name | SLU-PP-332 |
|---|---|
| Sizes | 5mg |
| Form | Lyophilised powder |
| Vial | 3 ml glass vial |
| Cap | Brushed silver-grey |
| CAS number | 303760-60-3 |
| Formula | C18H14N2O2 |
| Molar mass | 290.3 g/mol |
| Structure | A small molecule, 4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide. Not a peptide. |
| Storage | Store the dry solid sealed, cool and dark, with desiccant. |
| Certificate | On request, how to ask |
| Status | Sold out, stocking soon |
| Use | Laboratory research only |
Sources: PubChem compound record: SLU-PP-332 (CID 5338394), US National Library of Medicine. JPT Peptide Technologies, How to store peptides: best practices for researchers.
Regulatory status
In Australia
A text search of Australia's Poisons Standard, October 2026 edition, turned up no entry for SLU-PP-332. A missing listing does not mean the compound is approved, and this page takes no position on its legal standing.
SLU-PP-332 is an experimental compound, sold here strictly as a bench chemical for lab work, and anti-doping labs already study how to detect it.
Sources: Therapeutic Goods (Poisons Standard, October 2026) Instrument 2026 (F2026L01327), Federal Register of Legislation, Australian Government, Word copy searched 26 October 2026: 0 matches for SLU-PP. Moller T et al, Rapid Commun Mass Spectrom, 2026.
Testing
COA on request
Certificates of analysis are available on request. Ask us on WhatsApp before or after you order.
How ordering works
How to order
- 1
Fill your bag
Add compounds and quantities. No account needed.
- 2
Send on WhatsApp
One tap writes your whole order into a WhatsApp message.
- 3
Confirm and ship
We confirm stock and your total, share payment details, then ship tracked.
FAQ
Your questions
Is SLU-PP-332 a peptide?
No. It is a small synthetic molecule, a benzohydrazide, that acts on ERR nuclear receptors.
What does ERR mean?
Short for estrogen-related receptor. SLU-PP-332 switches on all three kinds, alpha, beta and gamma, in lab tests.
Is SLU-PP-332 orally bioavailable?
Not well. A 2026 mouse paper from the team that first made it says SLU-PP-332 lacks oral bioavailability. In mice, very little of an oral amount reached the bloodstream. The same paper described SLU-PP-915, a chemically distinct compound that is orally bioavailable. We found no human clinical trial records for SLU-PP-332 on PubMed or ClinicalTrials.gov.
Is SLU-PP-332 banned in sport?
The World Anti-Doping Agency Prohibited List we read for our guide does not name it. WADA's 2027 list, valid from 1 January 2027, adds SLU-PP-332, SLU-PP-915 and related substances as metabolic modulators. A 2026 lab study set out ways to detect it and its breakdown products, citing its doping potential.
Sources: PubChem compound record: SLU-PP-332 (CID 5338394), US National Library of Medicine. Billon C et al, ACS Chem Biol, 2023. Billon C et al, A synthetic ERR agonist alleviates metabolic syndrome, J Pharmacol Exp Ther, 2024. Moller T et al, Rapid Commun Mass Spectrom, 2026. Billon C et al, An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity, J Pharmacol Exp Ther, 2026. PubMed search "SLU-PP-332 AND clinical trial[pt]" (0 records) and ClinicalTrials.gov search for SLU-PP-332 (0 studies), both run 26 October 2026. World Anti-Doping Agency, Prohibited List, S4.4 metabolic modulators, read 26 October 2026. World Anti-Doping Agency, 2027 Prohibited List, S4.4.1, valid 1 January 2027.
In the catalogue
Related compounds
Questions before you order?
Ask on WhatsApp